{"organizations": [], "uuid": "6b7b64ae2a49292c686c987c869e1e879975f4ed", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/13", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/02/pr-newswire-free-research-reports-on-these-biotech-stocks--exelixis-insys-therapeutics-intellia-therapeutics-and-intercept-pharma.html", "country": "US", "domain_rank": 767, "title": "Free Research Reports on These Biotech Stocks -- Exelixis, INSYS Therapeutics, Intellia Therapeutics, and Intercept Pharma", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.548, "site_type": "news", "published": "2018-05-02T14:35:00.000+03:00", "replies_count": 0, "uuid": "6b7b64ae2a49292c686c987c869e1e879975f4ed"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/02/pr-newswire-free-research-reports-on-these-biotech-stocks--exelixis-insys-therapeutics-intellia-therapeutics-and-intercept-pharma.html", "ord_in_thread": 0, "title": "Free Research Reports on These Biotech Stocks -- Exelixis, INSYS Therapeutics, Intellia Therapeutics, and Intercept Pharma", "locations": [], "entities": {"persons": [], "locations": [{"name": "new york", "sentiment": "none"}, {"name": "south san francisco", "sentiment": "none"}, {"name": "california", "sentiment": "none"}], "organizations": [{"name": "intellia therapeutics", "sentiment": "negative"}, {"name": "exelixis", "sentiment": "negative"}, {"name": "exelixis inc.", "sentiment": "none"}, {"name": "intercept pharmaceuticals inc.", "sentiment": "none"}, {"name": "wallstequities.com", "sentiment": "none"}, {"name": "exel", "sentiment": "none"}, {"name": "insys therapeutics inc.", "sentiment": "none"}, {"name": "intellia therapeutics inc.", "sentiment": "none"}, {"name": "ntla", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, May 2, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on EXEL, INSY, NTLA, and ICPT which can be accessed for free by signing up to www.wallstequities.com/registration . Ahead of today's trading session, WallStEquities.com observes the recent performance of Exelixis Inc. (NASDAQ: EXEL), INSYS Therapeutics Inc. (NASDAQ: INSY), Intellia Therapeutics Inc. (NASDAQ: NTLA), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). These companies operate in the Biotechnology space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. All you have to do is sign up today for this free limited time offer by clicking the link below.\nwww.wallstequities.com/registration\nExelixis\nSouth San Francisco, California headquartered Exelixis Inc.'s stock finished Tuesday's session 0.86% higher at $21.00 with a total trading volume of 2.83 million shares. The stock is trading below their 50-day moving average by 10.54%. Shares of the Company, which engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer, have a Relative Strength Index (RSI) of 46.03.\nOn April 11 th , 2018, Exelixis announced that its Q1 2018 financial results will be released on May 02 nd , 2018, after the markets close. At 5:00 p.m. EDT that same day, management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available on the Company's website. Get the full research report on EXEL for free by clicking below at:\nwww.wallstequities.com/registration/?symbol=EXEL\nINSYS Therapeutics\nShares in Chandler, Arizona headquartered INSYS Therapeutics Inc. climbed 2.00%, ending yesterday's session at $7.15 with a total trading volume of 439,572 shares. The stock has gained 19.97% in the past month. The Company's shares are trading 3.66% above their 50-day moving average. Moreover, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have an RSI of 55.90.\nOn April 25 th , 2018, INSYS Therapeutics announced that it will release its Q1 2018 financial results on May 08 th , 2018, after the US financial markets close. Following the release, Saeed Motahari, President and CEO, and Andrew Long, CFO, will host a conference call at 5:00 p.m. EDT to discuss the results. Find your free research report on INSY at:\nwww.wallstequities.com/registration/?symbol=INSY\nIntellia Therapeutics\nOn Tuesday, Cambridge, Massachusetts headquartered Intellia Therapeutics Inc.'s stock rose 2.70%, to close the day at $20.56. A total volume of 908,262 shares was traded. The Company's shares have advanced 34.55% over the past year. The stock is trading 7.75% below its 200-day moving average. Additionally, shares of Intellia Therapeutics, which focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system, have an RSI of 41.39.\nOn April 23 rd , 2018, Intellia Therapeutics announced that two scientific abstracts have been accepted for presentation at the 21 st Annual Meeting of the American Society of Gene and Cell Therapy, taking place from May 16 th , 2018, to May 19 th , 2018, in Chicago. The first presentation will share information relating to the Company's lead in vivo program for transthyretin amyloidosis. The second will focus on its ongoing research collaboration with IRCCS Ospedale San Raffaele in Italy to develop CRISPR-edited, T-cell therapies to address hard-to-treat cancers. Sign up today for the free research report on NTLA at:\nwww.wallstequities.com/registration/?symbol=NTLA\nIntercept Pharmaceuticals\nShares in New York headquartered Intercept Pharmaceuticals Inc. ended the day 3.23% higher at $70.21. A total volume of 535,454 shares was traded. The stock has gained 17.02% in the last month and 4.67% in the previous three months. The Company's shares are trading above their 50-day moving average by 7.39%. Furthermore, shares of Intercept Pharma, which focuses on the development and commercialization of therapeutics in the US, Europe, and Canada, have an RSI of 54.65.\nOn April 24 th , 2018, Intercept Pharma announced that its Board of Directors has appointed Nancy Miller-Rich to fill a newly created directorship. Ms. Miller-Rich has 35 years of experience in the Healthcare industry, with significant expertise in business development and commercial strategy. Wall St. Equities' research coverage also includes the downloadable free report on ICPT at:\nwww.wallstequities.com/registration/?symbol=ICPT\n--\nWall St. Equities :\nWall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.\nWSE has not been compensated; directly or indirectly; for producing or publishing this document.\nPRESS RELEASE PROCEDURES :\nThe non-sponsored content contained herein has been prepared by a writer (the \"Author\") and is fact checked and reviewed by a third-party research service company (the \"Reviewer\") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com . Rohit Tuli, a CFAÂ® charterholder (the \"Sponsor\"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.\nNO WARRANTY\nWSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.\nNOT AN OFFERING\nThis document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit\nhttps://wallstequities.com/legal-disclaimer/\nCONTACT\nFor any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:\nEmail: info@wallstequities.com\nPhone number:+21-32-044-483\nOffice Address: 1 Scotts Road #24-10\nShaw Center Singapore 228\nCFAÂ® and Chartered Financial AnalystÂ® are registered trademarks owned by CFA Institute.\nView original content: http://www.prnewswire.com/news-releases/free-research-reports-on-these-biotech-stocks----exelixis-insys-therapeutics-intellia-therapeutics-and-intercept-pharma-300640984.html\nSOURCE Wall St. Equities", "external_links": ["http://www.wallstequities.com/registration/?symbol=NTLA", "https://wallstequities.com/legal-disclaimer/", "http://www.wallstequities.com/registration/?symbol=INSY", "http://www.wallstequities.com/registration/?symbol=ICPT", "http://www.prnewswire.com/news-releases/free-research-reports-on-these-biotech-stocks----exelixis-insys-therapeutics-intellia-therapeutics-and-intercept-pharma-300640984.html", "http://www.wallstequities.com/registration/?symbol=EXEL", "http://www.wallstequities.com/registration"], "published": "2018-05-02T14:35:00.000+03:00", "crawled": "2018-05-02T19:28:22.038+03:00", "highlightTitle": ""}